Author Archives: Patricia Inacio PhD

Genervon Presents Future Goals for Investigational GM6 Therapy in Parkinson’s, Other Diseases

Genervon Biopharmaceuticals announced its future goals for investigational therapy GM6 in a recent presentation on its multi-target drug development strategy to tackle neurodegenerative diseases, including Parkinson’s disease. Genervon presented its hypothesis that a multi-target drug approach is the key to curing complex neurological disorders at the 2018 BIO CEO…

Patient-on-a-Chip Program Could Benefit Parkinson’s Patients by Pinpointing Effective Treatment

A new personalized medical strategy that can replicate human biological systems in a small chip may help predict patients’ response to certain treatments based on their genetic makeup. Called Patient-on-a-Chip, the joint initiative by Cedars-Sinai and Emulate combines Cedars scientists’ expertise in stem cell technology with Emulate’s Human Emulation System,…

Wasp Venom Triggers Parkinson’s-Like Symptoms, Study Reports

The venom of the emerald cockroach wasp is capable of triggering Parkinson’s-like features, particularly problems controlling movement, a California study reports. Researchers said the findings on the venom’s toxins could lead to a better understanding of the mechanisms underlying Parkinson’s and new therapies. Their study, “Ampulexins: A New Family…

FDA Approves Osmolex, by Osmotica, to Treat Movement Problems in Parkinson’s and Other Adults

The U.S. Food and Drug Administration (FDA) has approved Osmolex ER (amantadine, extended release) to treat both Parkinson’s disease and therapy-induced extrapyramidal reactions in adults, or the movement and muscle-control problems that typify this disease and can be side effects of common medications. Osmodex ER, developed and marketed by Osmotica Pharmaceutical,…

Emerald Health Pharmaceuticals’ Cannabinoid-Derived Compound Beneficial in Parkinson’s, Mouse Study Finds

Emerald Health Pharmaceuticals investigational EHP-102 (previously known as VCE-003.2), a patented compound derived from the non-psychotrophic cannabinoid called cannabigerol, has shown anti-inflammatory and neuroprotective properties in a mouse model of Parkinson’s disease. The study “Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s…

NIH Creates Huge Public-Private Partnership to Try to Speed Parkinson’s Therapy Development

The U.S. National Institutes of Health is starting a pioneering, multi-pronged public-private partnership program to try to accelerate the development of Parkinson’s treatments. What makes it special is how big it is. The NIH-led collaboration includes government, pharmaceutical companies, life science companies and non-profit organizations. The partners are calling the collaboration AMP…

Denali to Test Higher Doses of Potential Parkinson’s Therapy on Healthy Volunteers, With FDA’s Blessing

Denali Therapeutics says its experimental therapy for Parkinson’s disease, DNL201 — a small-molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2) — stopped an average 90 percent of LRRK2 kinase activity at its highest concentration. When the drug’s levels dropped to the lowest concentration (known as trough levels), it still inhibited…